Winton Group LTD Protagonist Therapeutics, Inc Transaction History

Winton Group LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 28, 2021	SELL	$12.95 - $49.69 $70,331 - $269,866	-5,431 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$25.57 - $44.88 $138,870 - $243,743	5,431 New	5,431 $244,000
Q4 2020 Feb 12, 2021	SELL	$18.49 - $25.13 $607,470 - $825,621	-32,854 Closed	0 $0
Q3 2020 Oct 30, 2020	SELL	$15.19 - $22.4 $87,448 - $128,956	-5,757 Reduced 14.91%	32,854 $642,000
Q2 2020 Aug 05, 2020	BUY	$6.19 - $18.84 $5,125 - $15,599	828 Added 2.19%	38,611 $682,000
Q1 2020 May 11, 2020	SELL	$5.4 - $9.22 $281,194 - $480,113	-52,073 Reduced 57.95%	37,783 $267,000
Q4 2019 Feb 13, 2020	BUY	$4.69 - $13.45 $247,313 - $709,245	52,732 Added 142.04%	89,856 $633,000
Q3 2019 Nov 08, 2019	BUY	$9.41 - $16.56 $349,336 - $614,773	37,124 New	37,124 $446,000

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.